시장보고서
상품코드
1429357

세계 암 단클론항체 시장 보고서(2024년)

Cancer Monoclonal Antibodies Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

암 단클론항체 시장 규모는 향후 수년간 대폭적인 성장이 예상되고 있습니다. 2028년 복합 연간 성장률(CAGR) 9.8%를 나타낼 전망이며 959억 9,000만 달러로 성장할 것으로 예상되고 있습니다. 예측기간 동안 예상되는 성장은 암 유병률 증가, 세계 접근의 확대, 헬스케어 지출 증가에 의해 추진됩니다. 주요 동향은 전략적 협업을 통한 제품 혁신, 기술 진보, 인간화 된 암 모노클로 날 항체 개발, 연구 개발 비용 절감 및 의약품 개발 촉진을위한 AI 투자, 연구 개발 투자 증가 등이 포함됩니다.

세계 암 이환율의 급증은 암 단클론항체 시장의 확대에 크게 공헌하려고 하고 있습니다. 예를 들어 미국암협회의 데이터에 따르면 2022년 1월에는 미국에서만 약 190만명이 새롭게 암으로 진단되어 추정 60만9,360명의 암 관련 사망이 예측되고 있으며, 는 매일 약 1,670명의 사망자에 해당합니다. 세계적으로는 폐암, 전립선암, 장암, 여성 유방암의 4개의 가장 이환율이 높은 암이, 신규 암 증례 전체의 43%를 차지하고 있습니다. 그 결과, 세계 규모에서의 암 이환율의 상승에 의해 암 단클론항체 시장 수요가 높아질 것으로 예상됩니다.

암 단클론항체 시장의 예상 성장은 헬스케어 지출의 급증에 의해 더욱 가속됩니다. 건강 관리 지출에는 개인, 지역사회, 국가, 세계 수준에 관계없이 특정 기간 동안 의료 관련 서비스, 제품 및 노력에 할당된 총 금액이 포함됩니다. 헬스케어 분야에 대한 투자가 증가함에 따라 단클론항체 치료에 대한 개발, 접근성 및 조사가 크게 강화될 수 있습니다. 또한, 이러한 투자는 이러한 치료법의 제조와 제공에 있어서 최첨단 기술의 통합을 촉진합니다. 특히 국가 통계국은 2023년 5월 영국의 건강 관리 지출이 명목 9.4% 증가, 실질 9.7% 증가와 현저한 증가를 경험했다고 보고했습니다. 2021년 영국의 건강 관리 지출 총액은 3,672억 5,000만 달러(2,807억 파운드)에 이르렀고, 의약품 지출은 518억 4,000만 달러(396억 파운드)에 이르렀습니다. 게다가 예방의료 지출은 2021년 459억 3,000만 달러(351억 파운드)로 급증해 전년의 2배 이상이 되었습니다. 따라서 건강 관리의 상승은 가까운 미래에 암 단클론항체 시장의 성장 궤도를 추진하는 주요 원동력이 될 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 암 단클론항체 시장 : 단클론항체 치료별 세그먼테이션, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 베바시주맙(아바스틴)
  • 리툭시맙(리툭산)
  • 트라스투주맙(허셉틴)
  • 세툭시맙(아비택스)
  • 파니툼맙(벡티빅스)
  • 기타 단클론항체 요법
  • 세계 암 단클론항체 시장 : 용도별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 유방암
  • 혈액암
  • 간암
  • 뇌종양
  • 결장직장암
  • 기타 용도
  • 세계 암 단클론항체 시장 : 최종 사용자별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 병원 및 진료소
  • 연구
  • 약국
  • 기타 최종 사용자

제7장 지역 및 국가 분석

  • 세계 암 단클론항체 시장 : 지역별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 세계 암 단클론항체 시장 : 국가별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 암 단클론항체 시장 경쟁 구도
  • 암 단클론항체 시장 기업 프로파일
    • F. Hoffmann-La Roche Ltd
    • Merck &Co., Inc
    • Bristol Myers Squibb Company
    • Johnson &Johnson
    • Amgen Inc

제31장 기타 선도적이고 혁신적인 기업

  • AstraZeneca plc
  • Eli Lilly and Company
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi SA
  • Innovent Biologics
  • Sino biological
  • Shanghai Henlius Biotech
  • Intas bio
  • Zydus Cadila
  • Ranbaxy
  • Takeda pharmaceuticals
  • AbbVie Inc
  • Biogen Idec
  • Bayer AG

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

Cancer monoclonal antibodies are lab-created proteins designed to bind to specific targets, such as antigens on cancer cells. Each antibody is tailored to bind to a single antigen, resulting in a diverse range of monoclonal antibodies.

Key types of monoclonal antibody therapies for cancer include bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin, for example, is utilized for treating wet age-related macular degeneration and diabetic eye problems. Applications span breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and more. These therapies are utilized across various sectors, including hospitals, clinics, research laboratories, pharmacies, and others.

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The historical growth can be attributed to the growth of emerging markets, a rise in research and development (R&D) expenditure, an increased geriatric population, and a growing preference for biological treatments.

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. Anticipated growth in the forecast period is driven by the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure. Key trends include product innovation through strategic collaborations, technological advancements, the development of humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and expedite drug development, and increased R&D investments.

The surge in cancer incidences worldwide is poised to significantly contribute to the expansion of the cancer monoclonal antibody market. For instance, data from the American Cancer Society projected approximately 1.9 million new cancer diagnoses and an estimated 609,360 cancer-related deaths in the United States alone in January 2022, translating to roughly 1,670 fatalities daily. Globally, the four most prevalent cancer types - lung, prostate, bowel, and female breast cancer - collectively account for 43 percent of all new cancer cases. Consequently, the escalating rates of cancer incidence on a global scale are expected to drive heightened demand within the cancer monoclonal antibody market.

The anticipated growth of the Cancer Monoclonal Antibodies market is further fueled by an upsurge in healthcare expenditures. Healthcare expenditures encompass the aggregate amount allocated toward healthcare-related services, products, and endeavors over a specified period, whether at an individual, community, national, or global level. Increased investment in healthcare sectors can substantially bolster the development, accessibility, and research pertaining to monoclonal antibody treatments. Moreover, such investments facilitate the integration of cutting-edge technologies in the production and delivery of these treatments. Notably, the Office for National Statistics reported in May 2023 that healthcare spending in the UK experienced a notable upswing, with a nominal increase of 9.4% and a real increase of 9.7%. In 2021, the UK's total healthcare expenditure amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion). Additionally, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the escalating healthcare expenditure landscape is expected to be a key driver propelling the growth trajectory of the cancer monoclonal antibodies market in the foreseeable future.

Companies within the cancer monoclonal antibody market are actively pursuing product innovation through strategic collaborations as a means to sustain competitiveness in the industry. To navigate the increasingly competitive landscape, these companies are not only focusing on developing innovative products but also engaging in partnerships aimed at sharing skills and expertise. While partnerships with academic and research institutions have been a traditional practice in this sector, the trend of collaboration has notably intensified in recent years. As an illustration, in March 2023, BioNTech SE, a German biotechnology research company, entered into a partnership with OncoC4, Inc. This collaboration aims to jointly develop and commercialize an innovative checkpoint antibody targeting various solid tumor indications. BioNTech will gain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. The partnership outlines plans for joint development in solid tumor indications, including the initiation of a Phase 3 trial in 2023. Additionally, BioNTech will explore combination therapies and provide a $200 million upfront payment, alongside royalty payments, and potential milestone payments to OncoC4. OncoC4, Inc., based in the US, specializes in the clinical-stage development of biopharmaceuticals for cancer treatment.

Companies are directing their efforts toward pioneering biologic therapies, such as EPKINLY, to reinforce their market position. EPKINLY stands as an FDA-approved bispecific antibody designed for the treatment of advanced lymphoma. In a significant development in May 2023, AbbVie Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for EPKINLYTM (epcoritamab-bysp). This groundbreaking approval marks EPKINLY as the first and sole T-cell engaging bispecific antibody designated for treating adult patients grappling with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including instances originating from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone at least two rounds of systemic therapies.

In November 2021, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology company, successfully acquired Trillium Therapeutics for $2.22 billion. This strategic acquisition is geared towards expanding Pfizer's portfolio of biologics that boost the innate immune system, targeting both hematological malignancies and solid tumors. Trillium Therapeutics, headquartered in Canada, specializes in the development of innovative immunotherapies and antibody programs for cancer treatment.

Major companies operating in the cancer monoclonal antibodies market report are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc., Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Apotex, Gilead Sciences, Eurofarma, Teuto Brasileiro, BioMarin Pharmaceutical, BIONOVIS BRASIL, Ecopharm, Hypermarcas, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the cancer monoclonal antibodies market in 2023. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Monoclonal Antibody Therapies: Avastin; Herceptin; Keytruda; Opdivo; Darzalex; Perjeta; Others
  • 2) By Application: Breast Cancer; Blood Cancer; Lung Cancer; Brain Tumor; Colorectal Cancer; Cervical Cancer; Gastric Cancer; Others
  • 3) By End-User: Hospitals; Research Laboratories; Others
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Bristol Myers Squibb Company; Johnson & Johnson; Amgen Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Monoclonal Antibodies Market Characteristics

3. Cancer Monoclonal Antibodies Market Trends And Strategies

4. Cancer Monoclonal Antibodies Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Cancer Monoclonal Antibodies Market Size and Growth

  • 5.1. Global Cancer Monoclonal Antibodies Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Cancer Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Monoclonal Antibodies Market Segmentation

  • 6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Other Monoclonal Antibody Therapies
  • 6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Other Applications
  • 6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Clinics
  • Research Laboratories
  • Pharmacies
  • Other End Users

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

  • 7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Monoclonal Antibodies Market

  • 8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Monoclonal Antibodies Market

  • 9.1. China Cancer Monoclonal Antibodies Market Overview
  • 9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Monoclonal Antibodies Market

  • 10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Monoclonal Antibodies Market

  • 11.1. Japan Cancer Monoclonal Antibodies Market Overview
  • 11.2. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Monoclonal Antibodies Market

  • 12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Monoclonal Antibodies Market

  • 13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Monoclonal Antibodies Market

  • 14.1. South Korea Cancer Monoclonal Antibodies Market Overview
  • 14.2. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Monoclonal Antibodies Market

  • 15.1. Western Europe Cancer Monoclonal Antibodies Market Overview
  • 15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Monoclonal Antibodies Market

  • 16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Monoclonal Antibodies Market

  • 17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Monoclonal Antibodies Market

  • 18.1. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Monoclonal Antibodies Market

  • 19.1. Italy Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Monoclonal Antibodies Market

  • 20.1. Spain Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Monoclonal Antibodies Market

  • 21.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview
  • 21.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Monoclonal Antibodies Market

  • 22.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Monoclonal Antibodies Market

  • 23.1. North America Cancer Monoclonal Antibodies Market Overview
  • 23.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Monoclonal Antibodies Market

  • 24.1. USA Cancer Monoclonal Antibodies Market Overview
  • 24.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Monoclonal Antibodies Market

  • 25.1. Canada Cancer Monoclonal Antibodies Market Overview
  • 25.2. Canada Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Monoclonal Antibodies Market

  • 26.1. South America Cancer Monoclonal Antibodies Market Overview
  • 26.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Monoclonal Antibodies Market

  • 27.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Monoclonal Antibodies Market

  • 28.1. Middle East Cancer Monoclonal Antibodies Market Overview
  • 28.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Monoclonal Antibodies Market

  • 29.1. Africa Cancer Monoclonal Antibodies Market Overview
  • 29.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Monoclonal Antibodies Market Competitive Landscape
  • 30.2. Cancer Monoclonal Antibodies Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co., Inc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bristol Myers Squibb Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Johnson & Johnson
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Amgen Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Eli Lilly and Company
  • 31.3. Pfizer Inc
  • 31.4. Regeneron Pharmaceuticals Inc
  • 31.5. Sanofi S.A
  • 31.6. Innovent Biologics
  • 31.7. Sino biological
  • 31.8. Shanghai Henlius Biotech
  • 31.9. Intas bio
  • 31.10. Zydus Cadila
  • 31.11. Ranbaxy
  • 31.12. Takeda pharmaceuticals
  • 31.13. AbbVie Inc
  • 31.14. Biogen Idec
  • 31.15. Bayer AG

32. Global Cancer Monoclonal Antibodies Market Competitive Benchmarking

33. Global Cancer Monoclonal Antibodies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

35. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

  • 35.1 Cancer Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Cancer Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Cancer Monoclonal Antibodies Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제